Skip to main content
Premium Trial:

Request an Annual Quote

Merged Bruker Reports Increased Q3 Revenues

NEW YORK, Nov. 5, (GenomeWeb News) - Bruker BioSciences today reported revenues of $63 million for the third quarter ending Sept. 30, up over the $57 million for the year-ago quarter.


The company results reflect a merger-related charge of $6.4 million for the July 1 merger of Bruker Daltonics and Bruker AXS, and results from prior periods are historical combined reports of the two previously separate companies.


The company had a third-quarter net loss of $14.7 million, compared to a net income of $1.2 million for the year-ago quarter.


Bruker reported research and development costs of $9.6 million for the quarter, compared to $7.7 million for the same quarter last year. The firm reported cash, and short-term investments of $78 million for the quarter, as compared to $100 million for the year ago period.


The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.